'Company Overview
Company Type: Private Company
Website: www.igylifesciences.com
Number of Employees: -
Year Founded: 2009
Total Amount Raised (CAD mm)†: 0.07
Total Rounds of Funding**:1
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
IGY Immune Technologies & Life Sciences Inc. engages in the extraction of polyclonal antibodies for nutraceutical and pharmaceutical applications for human and animal consumption. Its antibodies are derived from chicken eggs. The company’s products are used in medicines, functional foods, agriculture/feeds, and cosmeceuticals. IGY Immune Technologies & Life Sciences Inc. was founded in 2009 and is based in Toronto, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Dyck, Terry
Chairman, Chief Executive Officer and President
La Russa, Nadia
Chief Financial Officer
Minstry, Jit
Director of Marketing
Cooke, Ian
Consultant
Iacopino, Anthony
Consultant
Qui, Wensheng
Consultant
Upton, Roger
Consultant

Key Board Members
Name
Title
Dyck, Terry
Chairman, Chief Executive Officer and President
Bux, Rashid Ahmed
Director
Jackson, Jeanette
Member of Advisory Board
Ly, Keith
Member of Advisory Board
Mauro, Frank
Member of Advisory Board
Sapra, Sheetal
Member of Advisory Board
Scott, Brian
Director
Webb, John
Member of Advisory Board


Primary Industry Classification
Pharmaceuticals


Primary Office Location
MaRS Centre West Tower 661 University Avenue Suite 1300 | Toronto, ON | M5G 0B7 | Canada
Phone: 807-343-6013   Fax: 807-623-2022


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Manufacturing Facility to Produce Purified IgY
As of April 30, 2012, Manufacturing Facility to Produce Purified IgY was acquired by IGY Immune Technologies & Life Sciences Inc. Manufacturing Facility to Produce Purified IgY comprises a facility that produces purified immunoglobulin Y (IgY) products from chicken egg yolks.

United States and Canada
Packaged Foods and Meats
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Apr-30-2012
Apr-30-2012
Merger/Acquisition
Buyer
Manufacturing Facility to Produce Purified IgY
IGY Immune Technologies & Life Sciences Inc.

-
Sep-19-2011
-
Private Placement
Target
IGY Immune Technologies & Life Sciences Inc.


0.07
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jun-09-2020
Strategic Alliances
IGY Life Sciences Partners with MMS Holdings to Develop Novel COVID-19 Antibody Treatment
Feb-20-2013
Product-Related Announcements
IGY Life Sciences Announces North American Launch of Vector450, an Athlete Immune Health Dietary Supplement
Apr-30-2012
M&A Transaction Closings
IGY Immune Technologies & Life Sciences Inc. acquired manufacturing facility to produce purified IgY.
Sep-19-2011
Private Placements
IGY Immune Technologies & Life Sciences Inc. announced that it expects to receive $0.03 million in funding.


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 20, 2023 05:02 AM
IGY Immune Technologies & Life Sciences Inc.
IGY Immune Technologies & Life Sciences Inc
Reports
23
GlobalData

Sep 15, 2023 09:52 AM
IGY Immune Technologies & Life Sciences Inc.
IGY Immune Technologies & Life Sciences Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
17
GlobalData

Jun 15, 2023 06:22 AM
IGY Immune Technologies & Life Sciences Inc.
IGY Immune Technologies & Life Sciences Inc
Reports
23
GlobalData

Jun 09, 2023 09:37 AM
IGY Immune Technologies & Life Sciences Inc.
IGY Immune Technologies & Life Sciences Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
17
GlobalData

Mar 21, 2023 04:24 AM
IGY Immune Technologies & Life Sciences Inc.
IGY Immune Technologies & Life Sciences Inc
Reports
24
GlobalData

Mar 10, 2023 06:31 AM
IGY Immune Technologies & Life Sciences Inc.
IGY Immune Technologies & Life Sciences Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
17
GlobalData

Dec 13, 2022 05:10 AM
IGY Immune Technologies & Life Sciences Inc.
IGY Immune Technologies & Life Sciences Inc
Reports
24
GlobalData

Dec 10, 2022 02:45 AM
IGY Immune Technologies & Life Sciences Inc.
IGY Immune Technologies & Life Sciences Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
17
GlobalData

Sep 16, 2022 07:43 PM
IGY Immune Technologies & Life Sciences Inc.
IGY Immune Technologies & Life Sciences Inc
Reports
24
GlobalData

Sep 15, 2022 12:18 AM
IGY Immune Technologies & Life Sciences Inc.
IGY Immune Technologies & Life Sciences Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
17


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Vector450

Key Board Members Details
Name
Title
Phone
Fax
Email
Dyck, Terry
Chairman, Chief Executive Officer and President
807-343-6013
807-623-2022
-
Bux, Rashid Ahmed
Director
807-343-6013
807-623-2022
-
Jackson, Jeanette
Member of Advisory Board
807-343-6013
807-623-2022
-
Ly, Keith
Member of Advisory Board
807-343-6013
807-623-2022
-
Mauro, Frank
Member of Advisory Board
807-343-6013
807-623-2022
-
Sapra, Sheetal
Member of Advisory Board
807-343-6013
807-623-2022
-
Scott, Brian
Director
807-343-6013
807-623-2022
-
Webb, John
Member of Advisory Board
807-343-6013
807-623-2022
-
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Dyck, Terry
Chairman, Chief Executive Officer and President
807-343-6013
807-623-2022
-
La Russa, Nadia
Chief Financial Officer
807-343-6013
807-623-2022
-
Minstry, Jit
Director of Marketing
807-343-6013
807-623-2022
-
Cooke, Ian
Consultant
807-343-6013
807-623-2022
-
Iacopino, Anthony
Consultant
807-343-6013
807-623-2022
-
Qui, Wensheng
Consultant
807-343-6013
807-623-2022
-
Upton, Roger
Consultant
807-343-6013
807-623-2022
-
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
